EyePoint Pharmaceuticals, Inc. (EYPT) P/E Ratio History
Deep ValueTrading at -4.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2010–2015
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) trades at a price-to-earnings ratio of -4.3x, with a stock price of $13.58 and trailing twelve-month earnings per share of $-3.16.
The current P/E is 131% below its 5-year average of 13.8x. Over the past five years, EYPT's P/E has ranged from a low of 7.8x to a high of 20.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, EYPT trades at a 119% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, EYPT trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EYPT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EYPT Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
EYPT P/E vs Peers
Ophthalmology Therapies and Delivery peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $63B | 14.7Lowest | 2.32Best | +8%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
EYPT Historical P/E Data (2010–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q2 | - | $37.70 | $1.86 | 20.3x | +47% |
| FY2015 Q1 | - | $39.50 | $2.25 | 17.6x | +28% |
| FY2014 Q4 | Dec 31 2014 | $41.10 | $3.16 | 13.0x | -6% |
| FY2014 Q3 | - | $44.20 | $3.25 | 13.6x | -1% |
| FY2011 Q2 | - | $42.80 | $3.91 | 10.9x | -21% |
| FY2011 Q1 | - | $39.20 | $2.52 | 15.6x | +13% |
| FY2010 Q3 | - | $43.80 | $3.84 | 11.4x | -17% |
| FY2010 Q2 | Jun 30 2010 | $36.10 | $4.65 | 7.8x | -44% |
Average P/E for displayed period: 13.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
What is EYPT's P/E ratio?
EyePoint Pharmaceuticals, Inc. (EYPT) trailing twelve-month P/E ratio is -4.3x, based on TTM diluted EPS of $-3.16. The 5-year average P/E is 13.8x and the historical range spans 7.8x to 20.3x.
Is EYPT stock overvalued or undervalued?
EYPT trades at -4.3x P/E, below its 5-year average of 13.8x. At the 0th percentile of its historical range (7.8x–20.3x), the stock is priced at a discount to its own history.
Is EYPT stock expensive?
No, EYPT is not expensive on a historical basis. The current P/E of -4.3x is below the 5-year average of 13.8x and sits at the 0th percentile of its valuation range.
What is EYPT's historical P/E range?
Over the past 5 years, EYPT's P/E ratio has ranged from 7.8x to 20.3x, with a median of 13.6x and an average of 13.8x. The current P/E of -4.3x places the stock at the 0th percentile of this range. Full historical data spans 2010–2015.
How does EYPT's P/E compare to the S&P 500?
EYPT trades at -4.3x P/E versus the S&P 500 median of 24.4x. The 118% discount to the market suggests lower growth expectations or perceived higher risk.
How does EYPT's valuation compare to Healthcare peers?
EyePoint Pharmaceuticals, Inc. P/E of -4.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is EYPT's PEG ratio?
EYPT PEG ratio is N/A, based on a P/E of -4.3x and EPS growth of -36.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is EYPT's earnings yield?
EYPT earnings yield is N/A, the inverse of its -4.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.